Background
Methods
Subjects
Patient follow-up and data collection
Study endpoints
Adverse effect assessment
Statistical analysis
Results
Patients’ characteristics
Median | Range | |
Age at diagnosis (years) | 70 | 58~81 |
Gland volume (mL) | 33.4 | 27~62 |
Follow-up (months) | 90 | 12~186 |
Count | Percentage (%) | |
Clinical stage | ||
T2b | 23 | 7.2 |
T2c | 167 | 52.2 |
T3a | 82 | 25.6 |
T3b | 48 | 15 |
Gleason score | ||
≤6 | 3 | 0.9 |
7 | 11 | 3.4 |
≥8 | 306 | 95.6 |
PSA at diagnosis (ng/mL) | ||
≤10 | 35 | 10.9 |
10~20 | 49 | 15.3 |
≥20 | 236 | 73.8 |
Memorial Sloan-Kettering risk classification | ||
2~3 IS | 71 | 22.2 |
1 HS | 106 | 33.1 |
2~3 HS | 143 | 44.7 |
MAB | ||
Continuous | 184 | 57.5 |
Intermittent | 136 | 42.5 |
PPB | ||
Yes | 203 | 63.4 |
No | 117 | 36.6 |
PSA nadir (ng/mL) | ||
≤1.0 | 241 | 75.3 |
>1.0 | 79 | 24.7 |
Time to PSA nadir (months) | ||
≤3 | 207 | 64.7 |
>3 | 113 | 35.3 |
PSA doubling time (months) | ||
≤12 | 46 | 14.4 |
>12 | 274 | 85.6 |
PSA decrease (%) | ||
<90 | 71 | 22.2 |
≥90 | 249 | 77.8 |
Factors influencing survival prognosis
Variable | Overall Survival | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
P Value | HR | P Value | HR | |
Age at diagnosis (years) ≤70 vs >70 | 0.035 | 5.812 | 0.174 | ―― |
Gland volume (mL) ≤33 vs >33 | 0.006 | 3.816 | 0.042 | 1.192 |
MAB Continuous vs Intermittent | 0.583 | ―― | 0.457 | ―― |
PPB yes vs no | 0.007 | 3.016 | <0.001 | 6.358 |
Clinical stage ≤ T2c vs ≥T3a | <0.001 | 4.557 | 0.011 | 2.183 |
Gleason score ≤7 vs ≥8 | 0.001 | 3.356 | <0.001 | 7.142 |
PSA at diagnosis (ng/mL) ≤10 vs 10~20 vs ≥20 | 0.027 | 1.558 | 0.014 | 3.492 |
Memorial Sloan-Kettering risk classification 2~3 IS vs 1 HS vs 2 HS | <0.001 | 7.658 | <0.001 | 5.479 |
PSA nadir (ng/mL) ≤1 vs >1 | <0.001 | 9.473 | 0.012 | 4.553 |
Time to PSA nadir (months) ≤3 vs >3 | 0.012 | 3.113 | 0.038 | 1.249 |
PSA doubling time (months) ≤12 vs >12 | 0.042 | 2.665 | 0.028 | 5.511 |
PSA decrease (%) <90 vs ≥90 | <0.001 | 13.463 | <0.001 | 7.845 |
Variable | Biochemical Recurrence-Free Survival | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
P Value | HR | P Value | HR | |
Age at diagnosis (years) ≤70 vs >70 | 0.339 | ―― | 0.147 | ―― |
Gland volume (mL) ≤33 vs >33 | 0.047 | 3.668 | 0.016 | 8.336 |
MAB Continuous vs Intermittent | 0.031 | 1.492 | 0.018 | 3.217 |
PPB yes vs no | 0.001 | 2.888 | <0.001 | 5.126 |
Clinical stage ≤ T2c vs ≥T3a | 0.041 | 4.737 | 0.013 | 6.142 |
Gleason score ≤7 vs ≥8 | 0.013 | 5.711 | 0.022 | 3.463 |
PSA at diagnosis (ng/mL) ≤10 vs 10~20 vs ≥20 | 0.019 | 2.622 | 0.001 | 6.334 |
Memorial Sloan-Kettering risk classification 2~3 IS vs 1 HS vs 2 HS | 0.027 | 1.772 | 0.009 | 3.643 |
PSA nadir (ng/mL) ≤1 vs >1 | 0.041 | 1.323 | 0.016 | 6.993 |
Time to PSA nadir (months) ≤3 vs >3 | 0.032 | 2.116 | 0.011 | 5.843 |
PSA doubling time (months) ≤12 vs >12 | 0.048 | 1.863 | 0.014 | 6.132 |
PSA decrease (%) <90 vs ≥90 | 0.006 | 3.677 | <0.001 | 9.385 |
Characteristics of high-risk patients treated with different RT regimens
Treatment | MAB+EBRT (n=117) | MAB+EBRT+PPB (n=203) | |
Median (Range) | Median (Range) | P Value | |
Age at diagnosis (years) | 70 (59~81) | 69 (58~79) | 0.11 |
Gland volume (mL) | 32.3 (27~62) | 34.6 (29~62) | 0.09 |
Follow-up (months) | 84 (12~186) | 90 (12~186) | 0.25 |
Count (%) | Count (%) | P Value | |
Clinical stage | |||
T2b | 9 (7.7) | 14 (6.9) | 0.32 |
T2c | 63 (53.8) | 104 (51.2) | |
T3a | 28 (23.9) | 54 (26.6) | |
T3b | 17 (14.5) | 31 (15.3) | |
Gleason score | |||
≤6 | 2 (1.7) | 1 (0.5) | 0.27 |
7 | 3 (2.6) | 8 (3.9) | |
≥8 | 112 (95.7) | 194 (95.6) | |
PSA at diagnosis (ng/mL) | |||
≤10 | 17 (14.5) | 18 (8.9) | 0.13 |
10~20 | 19 (16.2) | 30 (14.8) | |
≥20 | 81 (69.2) | 155 (76.4) | |
Memorial Sloan-Kettering risk classification | |||
2~3 IS | 27 (23.1) | 44 (21.7) | 0.61 |
1 HS | 38 (32.5) | 68 (33.5) | |
2~3 HS | 52 (44.4) | 91 (44.8) | |
MAB | |||
Continuous | 58 (49.6) | 126 (62.1) | 0.07 |
Intermittent | 59 (50.4) | 77 (37.9) |
PSA kinetics in high-risk patients treated with different RT regimens
Endpoint events in high-risk patients treated with different RT regimens
Complications in high-risk patients treated with different RT regimens
Adverse Effects | MAB+EBRT %(n=117) | MAB+EBRT+PPB %(n=203) | χ ² | P Value |
---|---|---|---|---|
Acute Urology Function | ||||
ABS Grade 0 | 12.82 | 5.42 | 5.447 | 0.020 |
ABS Grade 1 | 48.72 | 25.12 | 18.480 | 0.000 |
ABS Grade 2 | 20.51 | 31.53 | 4.516 | 0.034 |
ABS Grade 3 | 5.13 | 23.15 | 17.449 | 0.000 |
ABS Grade 4 | 12.82 | 14.78 | 0.235 | 0.628 |
Late Urology Function | ||||
Urgent/Incontinence | 1.71 | 1.48 | 0.026 | 0.872 |
Hesitancy/Retention | 1.71 | 3.45 | 0.821 | 0.365 |
Gross Hematuria | 4.27 | 6.4 | 0.635 | 0.426 |
Stricture | 0 | 0.49 | 0.578 | 0.447 |
Frequency/Nocturia | 15.38 | 25.12 | 4.162 | 0.041 |
Acute Gastrointestinal Function | ||||
RTOG Grade 0 | 90.6 | 88.67 | 0.291 | 0.590 |
RTOG Grade 1 | 5.13 | 5.91 | 0.086 | 0.769 |
RTOG Grade 2 | 3.42 | 3.45 | 0.000 | 1.000 |
RTOG Grade 3 | 0.85 | 1.97 | 0.601 | 0.438 |
RTOG Grade 4 | 0 | 0 | —— | —— |
Late Gastrointestinal Function | ||||
Diarrhoea | 21.37 | 13.3 | 3.549 | 0.060 |
Nausea/Vomiting | 7.69 | 4.93 | 1.017 | 0.313 |
Abdominal Pain | 4.27 | 3.94 | 0.021 | 0.885 |
Rectal Bleeding | 5.13 | 10.34 | 2.614 | 0.106 |
Intestinal Fistula | 0 | 0.49 | 0.578 | 0.447 |
Endocriology Function | ||||
Breast Pain | 69.23 | 63.05 | 1.250 | 0.264 |
Xerosis Cutis | 11.11 | 19.7 | 3.966 | 0.046 |
Hot Flush | 20.51 | 37.44 | 9.897 | 0.002 |
Sexual Dysfunction | 53.85 | 47.78 | 1.091 | 0.296 |
Other System Function | ||||
Liver Dysfunction | 5.13 | 8.37 | 1.172 | 0.279 |
Renal Dysfunction | 7.69 | 6.4 | 0.192 | 0.661 |
Angina Pectoris | 34.18 | 25.12 | 2.997 | 0.083 |
Heart Failure | 7.69 | 2.96 | 3.727 | 0.054 |
Dyspnea | 3.42 | 0.99 | 2.389 | 0.122 |
Anaemia(moderate/severe) | 16.24 | 16.75 | 0.014 | 0.906 |